
Tangen Biosciences Inc Profile last edited on: 9/6/19
CAGE: 6ZYQ1
UEI: K3D1V93LH4F8
Business Identifier: Next generation molecular diagnostics Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 03
County: New Haven
Congr. District: 03
County: New Haven
Public Profile
Tangen Bioscience had developed a medical instrument that provides rapid nucleic acid detection, with the specificity and sensitivity of polymerase chain reaction (PCR) amplification. The device provides rapid nucleic acid detection, in a format that does not require laboratory resources or highly skilled operators. These characteristics enable accurate detection of DNAs of interest directly from patient samples faster, simpler, at greater sensitivity, and at a lower cost than existing commercial technologies, all while being delivered in a portable form factor that does not require a laboratory.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2017 | 1 | NIH | $169,001 | |
Project Title: Rapid Detection of multiple sepsis pathogens | ||||
2016 | 1 | NIH | $216,030 | |
Project Title: Rapid Detection of Multiple Drug resistant TB from Sputum |
Key People / Management
John R Nobile -- Founder, President & Ceo
Richard Carroll -- VP Business Development and Regulatory Affair
John F Davidson -- CSO
Mark Holodniy -- Clinical Research Collaborato
Richard Carroll -- VP Business Development and Regulatory Affair
John F Davidson -- CSO
Mark Holodniy -- Clinical Research Collaborato
Company News
There are no news available.